ACAD
48.81
+0.99
+2.07%
AEMD
9.99
+0.19
+1.94%
APRI
1.44
+0.01
+0.70%
ARNA
4.04
+0.07
+1.76%
ATEC
1.36
0.00
0.00%
CNAT
4.74
-0.08
-1.66%
CRXM
0.3
0.00
0.00%
CYTX
0.44
+0.01
+2.33%
DXCM
84.65
+0.73
+0.87%
GNMK
8.5
+0.02
+0.24%
HALO
23.34
+0.21
+0.91%
ILMN
219.3
+0.43
+0.20%
INNV
0.155
0.00
0.00%
INO
7.29
+0.08
+1.11%
ISCO
0.043
0.00
0.00%
ISIS
54.93
+1.76
+3.31%
LGND
108.26
+0.48
+0.45%
LPTN
0.27
0.00
+0.15%
MBVX
2.16
+0.21
+10.77%
MEIP
1.56
-0.04
-2.50%
MNOV
3.75
+0.06
+1.63%
MRTX
28.61
+1.11
+4.04%
MSTX
0.447
0.00
-0.0447%
NBIX
50.12
+0.1
+0.20%
NUVA
55.01
+0.08
+0.15%
ONCS
6.06
-0.04
-0.66%
ONVO
3.38
+0.01
+0.30%
OREX
4
+0.05
+1.27%
OTIC
25.77
+0.26
+1.02%
QDEL
20.71
-0.25
-1.19%
RCPT
227.86
+0.38
+0.17%
RGLS
8.2
-0.06
-0.73%
RMD
57.95
+1.83
+3.26%
SCIE
0.018
-0.002
-10.000%
SPHS
0.87
-0.01
-1.1818%
SRNE
20.78
+0.39
+1.91%
TROV
7.88
+0.07
+0.90%
VICL
0.644
+0.014
+2.222%
ZGNX
19.31
0.00
0.00%
ACAD
48.81
+0.99
+2.07%
AEMD
9.99
+0.19
+1.94%
APRI
1.44
+0.01
+0.70%
ARNA
4.04
+0.07
+1.76%
ATEC
1.36
0.00
0.00%
CNAT
4.74
-0.08
-1.66%
CRXM
0.3
0.00
0.00%
CYTX
0.44
+0.01
+2.33%
DXCM
84.65
+0.73
+0.87%
GNMK
8.5
+0.02
+0.24%
HALO
23.34
+0.21
+0.91%
ILMN
219.3
+0.43
+0.20%
INNV
0.155
0.00
0.00%
INO
7.29
+0.08
+1.11%
ISCO
0.043
0.00
0.00%
ISIS
54.93
+1.76
+3.31%
LGND
108.26
+0.48
+0.45%
LPTN
0.27
0.00
+0.15%
MBVX
2.16
+0.21
+10.77%
MEIP
1.56
-0.04
-2.50%
MNOV
3.75
+0.06
+1.63%
MRTX
28.61
+1.11
+4.04%
MSTX
0.447
0.00
-0.0447%
NBIX
50.12
+0.1
+0.20%
NUVA
55.01
+0.08
+0.15%
ONCS
6.06
-0.04
-0.66%
ONVO
3.38
+0.01
+0.30%
OREX
4
+0.05
+1.27%
OTIC
25.77
+0.26
+1.02%
QDEL
20.71
-0.25
-1.19%
RCPT
227.86
+0.38
+0.17%
RGLS
8.2
-0.06
-0.73%
RMD
57.95
+1.83
+3.26%
SCIE
0.018
-0.002
-10.000%
SPHS
0.87
-0.01
-1.1818%
SRNE
20.78
+0.39
+1.91%
TROV
7.88
+0.07
+0.90%
VICL
0.644
+0.014
+2.222%
ZGNX
19.31
0.00
0.00%
Home » Bio: Jennifer Grodberg, PhD, RAC

Bio: Jennifer Grodberg, PhD, RAC

Jenny (Dr. Jennifer Grodberg) has over 19 years’ experience in the pharmaceutical industry. Currently she serves as Senior Director of Regulatory Affairs at Trius Therapeutics, a small pharmaceutical company developing antibacterial drugs for the treatment of infections caused by drug-resistant bacteria. Before working in regulatory affairs, she spent 10 years in anti-infectives drug discovery and technology/assay development, coordinating research programs from the identification of early drug leads through advancement to the IND enabling phase. Prior to entering the pharmaceutical industry, she held a faculty appointment at Harvard Medical School in the Department of Medicine. Jenny has a PhD in Microbiology, and completed post-doctoral work at both the Weizmann Institute of Science in Rehovot, Israel and Harvard Medical School. She obtained her RAC designation in 2007.
Jenny also serves as President of the American Medical Writers Association Pacific Southwest Chapter. This year she served as co-director of AMWA’s Pacific Regional Conference, and spent 2 years on the National organization’s executive committee as AMWA’s Annual Conference Workshop coordinator.